E. S. Kim’s scientific contributions

... Toxicity data suggest that the combination of an EGFR-TKI with RT is well tolerated [41]. In a phase II study of erlotinib plus concurrent WBRT in patients with brain metastases from NSCLC, Welsh and colleagues suggested that the activation of EGFR leads to radiation resistance and that use of an EGFR-TKI could overcome this resistance [42]. Moreover another TKI, crizotinib, has recently been shown to have superior intracranial efficacy, as compared to chemotherapy, in patients with advanced ALK-positive NSCLC with brain metastases [43]. ...

Reference:

Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG)